Martin Bonacci

Martin Bonacci is a seasoned professional in the field of clinical development, currently serving as Sr Director at Boehringer Ingelheim since August 2021. In this role, Martin leads global clinical development programs from preclinical models to proof-of-concept trials, collaborating with regulatory agencies like the FDA and EMA while focusing on end-stage liver disease. Prior to this, Martin was Director of Medical Affairs at Intercept Pharmaceuticals, where responsibilities included the development of medical strategies for metabolic dysfunction-associated steatohepatitis and mentoring medical advisors. Martin's extensive research background includes postdoctoral work at Hospital Clínic de Barcelona on nonalcoholic steatohepatitis and a PhD in Medicine from Universitat de Barcelona. Additionally, Martin has experience as the Liver Transplant Center Director at Clinica Pueyrredon and as a Clinical Trial Investigator at Instituto de Investigaciones Clínicas in Argentina. Martin holds a Master's degree in Liver Diseases from Universitat de Barcelona.